Document is current
Any future updates will be listed below
-
Authors
Fromme, Malin
Remih, Katharina
Strnad, Pavel
-
Funding
Funding for this research was provided by:
SFB 1382 (403224013)
SFB 1382 (403224013)
Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at RWTH Aachen University (PTD 1-3)
Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at RWTH Aachen University (PTD 1-3)
CSL Behring
- License Information
-
More Information
Article History
Received: 12 August 2025
Accepted: 10 March 2026
First Online: 17 April 2026
Declarations
:
: not applicable.
: not applicable.
: M.F. received consulting fees from Takeda Pharmaceuticals and honoraria from CSL Behring, Grifols Inc and Takeda Pharmaceuticals.P.S. reports receiving grants and honoraria from Arrowhead Pharmaceuticals, CSL Behring, Grifols Inc, consulting fees or honoraria from Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, Dicerna Pharmaceuticals, GSK, Intellia Pharmaceuticals, Takeda Pharmaceuticals, Novo Nordisk and Ono Pharmaceuticals, participating in leadership or fiduciary roles in Alpha1-Deutschland, Alpha1 Global, and material transfer support for Vertex Pharmaceuticals and Dicerna Pharmaceuticals.
